The FDA has approved Enbumyst offering a self-administered outpatient option for managing edema in patients with heart failure, liver disease, and kidney disease.
Debate continues over school head lice policies as parents call for stricter exclusion rules while public health guidance supports in-class management.
KFF Health News
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
The FDA approved Bildyos and Bilprevda are providing new options comparable to Prolia and Xgeva for osteoporosis, cancer-related bone disease, and other skeletal conditions.